BeiGene celebrates profit milestone on soaring drug sales 澤布替尼海外市場銷量走高 百濟神州首次實現季度盈利
Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis 今年第一季度百濟神州GAAP凈利潤為127萬美元，2024年同期凈虧損2.51億美元。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.